Aerovance is a biopharmaceutical company focused on the development and commercialization of clinical-stage products for respiratory and allergic diseases. The company's goal is to build an integrated company, with acknowledged expertise in leveraging operational partnerships that include the discovery, development and commercialization of novel molecules. Aerovance’s lead programs are in development for the treatment of uncontrolled asthma and uncontrolled eczema. Other programs in the pipeline are for cystic fibrosis and chronic obstructive pulmonary disease.
Aerovance was spun off from Bayer Healthcare's biotechnology unit in August 2004 and has a proven executive team, experienced in the field of respiratory disease and biologics drug development. The company’s venture capital investors are Alta Partners, APAX Partners, Burrill & Company, Clarus Ventures, Lehman Brothers and NGN Capital.
